12/27/07
VGX Pharmaceuticals announces successful completion of the first human study to assess the tolerability of CELLECTRA™ electroporator
12/20/07
VGX Pharmaceuticals announces IND filing of VGX-1027, a novel small molecule compound with potent anti-inflammatory activity
12/13/07
VGX Pharmaceuticals announces the discontinuation of VGX-410C development
and the concentration of its efforts on HIV and other product pipelines
11/12/07
VGX Pharmaceuticals' SynCon™ Pandemic Flu Vaccine Protects Against A Lethal Challenge of Live Virus in Pre-Clinical Animal Models
11/7/07
VGX Pharmaceuticals Announces Executive Promotions
10/29/07
VGX Pharmaceuticals announces an agreement with VGX International to build a large scale cGMP DNA manufacturing plant in Korea
10/24/07
VGX Pharmaceuticals adds cGMP plasmid DNA manufacturing capacity
10/17/07
VGX Pharmaceuticals provides clinical trials and product development updates
10/8/07
VGX Pharmaceuticals to present at the Second International Conference on Cancer Vaccines/Adjuvants/Delivery
9/19/07
VGX Pharmaceuticals closes investment by the Korea Development Bank
9/10/07
VGX Pharmaceuticals Receives $1.9 Million Contract from U.S. Government to Develop Skin Micro-Electroporation for Improved Biodefense Vaccine Efficacy
9/2/07
VGX Pharmaceuticals Announces the Completion of Patient Enrollment for the Company’s Phase II Trial for VGX-410C
8/20/07
VGX DNA vaccine primate study results to be presented at the AIDS Vaccine 2007 Conference
8/15/07
VGX Pharmaceuticals Announces Initiation of IND-enabling Toxicology Studies for Candidate DNA Vaccine Products
7/19/07
VGX Pharmaceuticals Announces Issuance of a Key U.S. Patent Covering New Electroporation Technology for Delivery of Macromolecules to Cells
7/17/07
VGX strengthens its plasmid position
7/11/07
VGX Pharmaceuticals Announces Issuance of Two Key U.S. Patents Covering DNA Plasmid Manufacturing Technology and the Treatment of Anemia
7/1/07
VGX Pharmaceuticals Announces Promotion of Bryan Kim, D.M.D. to Vice President of Asian Operations
6/20/07
VGX Pharmaceuticals Announces an R&D and License Agreement with VGX International to Develop Gastric Cancer Therapeutics
6/15/07
VGX International Inc. Added to the KOSPI 200 Index
5/31/07
VGX Pharmaceuticals Announces Formation of Animal Health Company
5/30/07
VGX Pharmaceuticals to Present at American Society of Gene Therapy Meeting
5/23/07
VGX Pharmaceuticals' Novel HIV and Pandemic Influenza DNA Vaccine Candidates Trigger Robust Immune Responses and Protection in Pre-Clinical Models
5/21/07
BusinessWeek: Development to Watch - VGX Pharmaceuticals
5/21/07
VGX Pharmaceuticals Co-Founder Professor David B. Weiner to Chair International Scientific Congress
5/14/07
VGX Pharmaceuticals Announces DNA Therapeutics License Agreement with Baylor College of Medicine
5/8/07
VGX Pharmaceuticals Announces Publication of Preclinical Efficacy Studies for VGX-1027 for Various Inflammatory Diseases
5/4/07
VGX Pharmaceuticals Announces Agreement with Diosynth Biotechnology for Process Development and Clinical Production of VGX-100 for the Treatment of Cancer
5/2/07
VGX Pharmaceuticals Strengthens Management Team with Two New Appointments: Dorothy Peterson Appointed as Director of Quality, Debra A. Bacino Appointed as Controller
5/1/07
VGX Pharmaceuticals Licenses Pfçnex Expression Technology™ from Dowpharma
SM
for the Production of VGX-100
4/24/07
VGX Pharmaceuticals Announces DNA Vaccines License Agreement with University of Pennsylvania
3/12/07
VGX Pharmaceuticals announced the appointment of Thomas S. Kim, J.D. as Senior Director, Intellectual Property
2/26/07
VGX Pharmaceuticals and ADViSYS Announce Merger Agreement: Creation of VGX Immune Therapeutics Division
2/21/07
VGX Pharmaceuticals Signs Marketing and License Agreement for Asia and Other Developing Regions
1/17/07
Annual Update Letter to Our Shareholders
1/2/07
VGX Pharmaceuticals Announces Promotion of Niranjan Y. Sardesai, Ph.D., to Vice President of Product Development
© 2008 VGX™ Pharmaceuticals. All rights reserved.
